BUZZ-Avidity Biosciences rises on report of Novartis buyout deal
I'm PortAI, I can summarize articles.
Shares of drug developer Avidity Biosciencesrise 17.6% to $44.99 Swiss drugmaker Novartis (NOVN.S) has approached U.S. biotech Avidity with a potential takeover offer to boost its drug pipeline, the Financial Times reported “As a matter of policy, we do not comment on rumors or speculation” - Avidity Avidity has a market capitalisation of $4.61 billion, according to data compiled by LSEGIncluding session’s moves, stock up ~23% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments